On October 28, 2025, Guangzhou BeBetter Med Inc.(hereinafter “BeBetter Med,” stock code: 688759.SH) successfully listed on the STAR Market, opening a new chapter in its capital journey. BeBetter Med publicly issued 90 million shares at an offering price of RMB 17.78 per share, with the proceeds primarily earmarked for new drug R&D, the construction of an R&D center, and a formulation industrialization base.
Founded in 2012, BeBetter Med’s management team, core technical staff, and expert panel include several returnee PhDs, specially appointed experts under national major talent programs, entrepreneurs, and experienced operations managers. The team possesses rich domestic and international drug R&D and corporate management experience. The company has been selected as a Technology Leading Talent in the Guangzhou Development District, an Innovation & Entrepreneurship Team under Guangdong’s “Pearl River Talent Plan,” and a Guangzhou Entrepreneurship Leading Team. BeBetter Med has been awarded the Guangdong Postdoctoral Innovation Practice Base, recognized as Guangdong Province’s Class-I New Drug Discovery and Industrialization Engineering Technology Research Center, and honored as a Guangzhou “Future Unicorn” innovative enterprise as well as a Guangzhou “High-Precision & Cutting-Edge” enterprise.
BeBetter Med’s core product, BEBT-908, as the world’s first approved small-molecule dual-target inhibitor, received conditional approval for marketing from the Center for Drug Evaluation of the National Medical Products Administration (CDE) on June 30, 2025, for third-line and later treatment of relapsed or refractory diffuse large B-cell lymphoma (r/r DLBCL). The company is currently actively advancing commercialisation of this product. In addition to BEBT-908, the pipeline includes BEBT-209, which is in Phase III clinical trials; BEBT-109, which has been approved to commence Phase III trials; and five other products currently in Phase I trials.



Glory Fund deeply endorses the company’s “clinical value–oriented” R&D philosophy and is optimistic about its long-term potential in the innovative pharmaceutical field. We believe that, guided by the vision “relentless innovation, pursuing better,” BeBetter Med will bring new treatment options to patients and create long-term value for investors.
Congratulations to BeBetter Med on embarking on a new journey and forging new achievements!